Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with
liver metastasis treated with Trans-arterial Tirapazamine Embolization along with
Pembrolizumab.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04701476.
Locations matching your search criteria
United States
California
Orange
UC Irvine Health/Chao Family Comprehensive Cancer CenterStatus: Active
Contact: Cindy Duong
This study is an open-label study to treat patients with refractory metastatic colorectal
cancer and non-small cell lung cancer with liver metastasis. Patients enrolled in the
mCRC cohort will be randomized to receive study treatment Trans-arterial Tirapazamine
Embolization (TATE)+Pembrolizumab or FDA-approved standard of care, such as TAS-102 or
regorafenib, and their Overall Survival (OS) will be compared in the two cohorts as the
primary endpoint. Patients enrolled in the NSCLC cohort will all receive study treatment
TATE+Pembrolizaumb and Overall Response Rate (ORR) will be the primary endpoint.
Lead OrganizationTeclison Ltd.
